Needham Reiterates Buy on Viridian Therapeutics, Maintains $30 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Serge Belanger has reiterated a Buy rating on Viridian Therapeutics (NASDAQ:VRDN) and maintained a $30 price target.
May 09, 2024 | 9:29 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Serge Belanger reiterates a Buy rating on Viridian Therapeutics and maintains a $30 price target.
The reiteration of a Buy rating and maintenance of a $30 price target by a reputable analyst suggests a positive outlook for VRDN, likely leading to increased investor confidence and potential upward movement in the stock's price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100